Prostamax, prostatta birincil onarım etkileri olan sentetik bir khavinson peptididir [1]. Peptit ayrıca lenfosit fonksiyonunu geliştirdiği ve diğer dokulardaki DNA ekspresyon paternlerini değiştirdiği gösterilmiştir. ProStamax, daha geniş spektrumlu yaşlanma karşıtı Khavinson peptitlerinden biri olarak kabul edilir, çünkü çok çeşitli hücrelerde heterokromatinin dekonderlenmesini teşvik eder. Sıçanlarda yapılan araştırmalar, prostamax'ın kronik prostatit tedavisinde yararlı olabileceğini göstermektedir. Uzun süreli kullanımın kanseri ortadan kaldırabileceğine dair spekülasyonlar vardır, ancak bunu göstermek için yeterli uzunlukta çalışmalar henüz yapılmamıştır.

Amino Acid Sequence: Lys-Glu-Asp-Pro (KEDP) Molecular Formula: C₂₀H₃₃N₅O₉ Molecular Weight: 487.5 g/mol PubChem CID: 9848296 Synonyms: SCHEMBL6660498 Source: PubChem

Chronic prostate inflammation (called chronic prostatitis) affects as many as 16% of men at some point in their lives. It is a painful condition causing burning with urination, urgency, and trouble voiding. It can even cause difficult or painful ejaculation along with pain in the lower back. It is notoriously difficult to treat, often requiring long-term antibiotic treatment over months. There is also good evidence to suggest that it can lead to cardiovascular disease and even cancer, so treating prostatitis is crucial to long-term health[2]. Research in rat models shows that prostatitis can be treated with Prostamax, which reduces the signs and symptoms of the disease. Rats treated with Prostamax for just 15 days showed reduce swelling of the prostate gland along with less vascular congestion (hyperemia) and less infiltration by cells of the immune system. Interestingly, the rats also showed decreased levels of scarring in the prostate, indicating that the reduction in inflammation was slowing or even stopping pathological remodeling. Though the study was not carried out long enough or on enough rats to assess Prostamax’s effect on the risk for cancer, the results suggest that it would likely diminish the risk by reducing chronic inflammation that leads to pathological hypertrophy and hyperplasia[3]. According to Dr. Angelina Pakhomova, what makes the above study on Prostamax extra exciting is that it was effective in treating a form of prostatitis called chronic abacterial prostatitis (CAP). CAP is the most common form of prostatitis, but it is difficult to treat because it isn’t caused by a bacterial infection. Bacterial infections respond readily to antibiotics. CAP, on the other hand, does not respond as well to antibiotic treatment and sometimes doesn’t respond at all. It is also more likely to recur and has been shown to be exceptionally frustrating to those who suffer from it. Having an alternative treatment that is effective in CAP could improve quality of life for many men and ward off future disease. Finding a treatment for CAP is more important than ever as rates of the condition have increased almost 3-fold since the end of the 20^th century.

Prostamax ve bağışıklık sistemi

Though Prostamax is considered to be tissue-specific, there is ample evidence that the bioreulator acts on cells outside of the prostate. The most consequential effects are on the ribosomes and densely packed chromatin found in lymphocytes. In these cells, Prostamax, like Epithalon and Vilon, serves to increase expression of ribosomes which are responsible for the translation of mRNA into proteins. It also opens up densely packed chromatin to make genes more accessible for transcription into mRNA. Thus, Prostamax sets the stage for increased gene expression at every level, allowing for a functional change in the health of lymphocytes[4], [5]. The impact of Prostamax on the immune system is not just theoretical either. Research shows that the peptide helps to reduce signs of chronic prostate inflammation including swelling, hyperemia, and lymphocyte infiltration.[3] This results both from the influence Prostamax has on lymphocytes and their control over the immune response as well as the role the peptide plays in normalizing growth and differentiation of prostate cells.

Prostamax ve yaşlanma

The effects that Prostamax has on lymphocytes and cells of the prostate are part of a larger effect it has one many different types of cells. Research in cell cultures taken from older individuals shows that Prostamax alters DNA structure by decondensing heterochromatin. This, in turn, allows for greater expression of DNA that was inactivated via dense packaging of DNA[6]. What makes this remarkable in terms of aging is that condensation of DNA is a normal, if undesirable, consequence of aging. DNA condensation is a primary driver of both senescence and apoptosis, making it one of the most important mechanisms of aging. By unpacking DNA, Prostamax is literally giving the cells a more youthful genetic profile. The results are increased proliferation of cells, decreased apoptosis (programmed cell death), and improved protein expression and cell function. Interestingly, Prostamax and similar epigenetically active peptides are found naturally in long-lived rodent species like the African mole rat. These same peptides are Olumsuz found in short-lived species[7]. This indicates that the epigenetic effects that have been observed with peptides like Prostamax are, in fact, directly related to aging and longevity.

Prostamax özeti

Prostamax, bir dizi hücrede DNA yoğunlaşması üzerinde derin etkileri olan sentetik bir khavinson peptididir. Öncelikle prostat üzerindeki yaşlanma karşıtı ve anti-enflamatuar etkileri için ilgi çekici olsa da, prostamax'ın DNA üzerindeki epigenetik kontrolleri değiştirerek vücuttaki bir dizi hücrenin (örn. Lenfositler) fonksiyonunu optimize ettiği gösterilmiştir.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Rus ve Ukrayna Tıp Bilimleri Akademileri; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Rusya Bilimler Akademisi; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptit bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotörler. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries. Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Prostamax. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between

1. A. N. Zakutskiĭ, N. I. Chalisova, G. A. Ryzhak, A. I. Aniskina, S. V. Filippov, and P. N. Zeziulin, “[The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats],” Adv. Gerontol. Uspekhi Gerontol., cilt. 19, s. 93–96, 2006.
2. “Treating chronic prostatitis,” Harvard Health, 21 Aralık 2017.
3. T. G. Borovskaya et al., “Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications,” Mod. Res. Inflamm., cilt. 2013, Temmuz 2013, iki: 10.4236/MRI.2013.23007.
4. V. K. Khavinson, T. A. Lezhava, and V. V. Malinin, “Effects of short peptides on lymphocyte chromatin in senile subjects,” Bull. Exp. Biol. Med., cilt. 137, hayır. 1, s. 78–81, Ocak 2004, doi: 10.1023/b: Babm.0000024393.40560.05.
5. T. Meskhi et al., “[The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ],” Biofizika, cilt. 49, hayır. 6, s. 1091-1093, Aralık 2004.
6. T. A. Dzhokhadze, T. Z. Buadze, M. N. Gaĭozishvili, N. A. Baratashvili, and T. A. Lezhava, “[Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)],” Georgian Med. News, kapalı. 212, s. 76-82, Kasım 2012.
7. V. K. Khavinson, D. Y. Kormilets, and A. T. Mar’yanovich, “Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan,” Bull. Exp. Biol. Med., cilt. 163, hayır. 5, s. 671-676, Eylül 2017, doi: 10.1007/s10517-017-3876-x.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. Bu web sitesinde sunulan ürünler sadece vitro çalışmalar için döşenmiştir. Vücudun dışında in vitro çalışmalar (Latin: camda) yapılır. Bu ürünler ilaç veya ilaç değildir ve herhangi bir tıbbi durum, rahatsızlık veya hastalığı önlemek, tedavi etmek veya iyileştirmek için FDA tarafından onaylanmamıştır. İnsanlara veya hayvanlara her türlü bedensel olarak tanıtılması, yasalarca kesinlikle yasaktır.